Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents
Expert Opinion on Drug Safety August 15, 2023 DOI: 10.1080/14740338.2023.2248883 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | LSD Psilocybin Serotonin |
| Keywords | Agonism 5-HT Receptor Pharmacology Serotonin antagonists Hallucinogen |
| Citations | 26 |
| Key points | Psilocybin, LSD, and ecstasy may pose a risk of valvular heart disease via 5HT2B receptor agonism, as noted in FDA guidance. |
Abstract
KEYWORDS: PsilocybinLysergic acid diethylamide (LSD)ecstasyvalvular heart disease5HT2B receptor agonismFDA guidance